Leadership transition at Pratia to support global growth

Pratia is pleased to announce a strategic leadership evolution that supports the company’s continued global expansion and further strengthens its integrated clinical research operations.

Łukasz Bęczkowski appointed Global Chief Executive Officer

Effective immediately, Łukasz Bęczkowski, who has served as Pratia’s Chief Operating Officer for the past five years, assumes the role of Global Chief Executive Officer.

Łukasz brings a deep operational understanding of the organization, a strong leadership track record, and a clear vision for guiding Pratia through its next stage of innovation and international expansion. In his new role, Łukasz will focus on accelerating international growth, advancing operational excellence, and strengthening partnerships with Sponsors and CROs across multiple therapeutic areas.

Tomek Dąbrowski becomes Executive Chair of Pratia

As part of this transition, Tomek Dąbrowski, co-founder and Chief Executive Officer of Pratia for over twelve years, moves into the role of Executive Chair of Pratia. He will continue to serve as HUMANEVA Group CEO.

Tomek will focus on scaling the Group’s 2,000-strong organization across four continents and twelve countries, strengthening a unified corporate culture, and driving strategy execution across all business lines.

Tomasz Groń appointed Vice President Operations Europe

To support Pratia’s continued growth, and ensure strong operational leadership, the company has appointed Tomasz Groń as Vice President Operations Europe.

In his role, Tomasz oversees operations across seven European countries and focuses on strengthening execution, scalability, and consistency across Pratia’s European Research Sites. He brings over 20 years of experience in large, multi-country organisations, with proven success in scaling operations, expanding multi-site networks, and introducing  data-driven and omnichannel initiatives that support sustainable growth.

Strong foundation in oncology and beyond

Oncology remains one of Pratia’s key therapeutic strengths, representing a quarter of the company’s experience. Pratia operates nine exclusive oncology units across eight countries and collaborates with multiple embedded hospital Research Sites globally, enabling efficient access to oncology Patients and consistent study delivery.

This leadership transition reinforces Pratia’s commitment to supporting Sponsors with reliable, high-quality Clinical Trials, delivered through an integrated and scalable global platform.

Pratia congratulates Łukasz, Tomek and Tomasz on their appointments and looks forward to continued growth under their leadership, supported by the HUMANEVA Group.